Sign inJoin waitlistJoin the waitlist

Tomas Aleman

Co-Director · University of Pennsylvania Health System

Credentials: · · ·

History

University of Pennsylvania Health System
Present
University of Pennsylvania Health System
Present
Children's Hospital of Philadelphia
Present

Ophthalmology
Hospital Salvador Allende
2015–2019
Internal Medicine
One Brooklyn Health System-Brookdale University Hospital Medical Center
2012–2015
Hospital Salvador Allende
2011–2012
FAC DE CIENCIAS MEDICAS MATAMZAS/UNIV OF HAVANA, CUBA
1984–1988

Research

Gene therapy restores vision in a canine model of childhood blindness
Nature Genetics · 2001 · 917 citations
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial
Human Gene Therapy · 2008 · 814 citations
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics
Proceedings of the National Academy of Sciences of the United States of America · 2008 · 580 citations

Samuel Jacobson
85 papers
Edwin Stone
38 papers · 25 as a resident
Albert Maguire
34 papers
Erin O'Neil
18 papers · 7 as a resident
Alexander Brucker
11 papers
Benjamin Kim
10 papers
Katherine Uyhazi
10 papers · 2 as a resident
BL
Bart Leroy
8 papers
SK
Shalesh Kaushal
8 papers
AS
Anand Swaroop
6 papers
Byron Lam
6 papers · 2 as a resident
Charles Nichols
6 papers

Grants

Gene Therapy for LCA5-Assocated Inherited Retinal Degeneration: Extension to Pediatric Cohorts
Food and Drug Administration · R01
Contact PI · $2.5M · University of Pennsylvania
2024–2028

Clinical trials

Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)
Principal investigator · Active not recruiting
Genentech, Inc.
2015–2030
Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
Site PI · Not yet recruiting · Phase 1, Phase 2
Opus Genetics, Inc
2026–2034
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
Site PI · Recruiting · Phase 3
Atsena Therapeutics Inc.
2023–2033
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
Site PI · Recruiting · Phase 1, Phase 2
Opus Genetics, Inc
2023–2028